Chemistry: analytical and immunological testing – Clotting or clotting factor level tests
Patent
1990-09-27
1993-03-09
Hill, Jr., Robert J.
Chemistry: analytical and immunological testing
Clotting or clotting factor level tests
435 13, G01N 3386
Patent
active
051926890
ABSTRACT:
A method for determining the endogenous thrombin potential (ETP), which shows how much and for what length of time thrombin has been active in a sample of clotting blood or plasma. The ETP can be used for determining the effectiveness of treatment with antithrombotics of any type. Thus, the ETP determination comprises adding to a sample a thrombin substrate, an activator of thrombin formation, a preparation of proteaseinhibitor and if desired a pharmaceutical for analysis. The thrombin substrate is preferably selected to not completely consume the amount of thrombin generated in the sample, to have a rate of conversion of the substrate which is proportional to the amount of thrombin present and to have a measurable conversion product resulting from the conversion by thrombin. Determination of the amount of conversion product leads to determination of the ETP. The choice of activator determines whether the effect is measured on the intrinsic or extrinsic clotting system, making it possible to determine the effect of the pharmaceutical, which is being analyzed, on various parts of the clotting mechanism.
REFERENCES:
patent: 4061625 (1977-12-01), Af Ekenstam et al.
patent: 4169015 (1979-09-01), Af Ekenstam et al.
patent: 4247454 (1981-01-01), Af Ekenstam et al.
patent: 4508644 (1985-04-01), Heber et al.
patent: 4594326 (1986-06-01), Wade
patent: 4672030 (1987-06-01), Witt
patent: 4851336 (1989-07-01), Yin
Becker et al, Clin. Chem., vol. 30, No. 4, pp. 524-528, 1984.
Van Wijk et al. Clin. Chem, vol. 26, No. 7, pp. 885-890, 1980.
Yamada et al, Thrombosis Research, vol. 15, pp. 351-358, 1979.
"Thrombosis and Thrombin", Biology and Pathology of Platelet-Vessel Wall Interactions, Chapter 13, 1986, By. H. Hemker et al., pp. 219-226.
"The Generation of Thrombin in Whole Plasma", Verhandelingen Van De Koninklijke Academie Voor Geneeskunde Van Belgie, No. 5, 1985, By H. Hemker et al., pp. 321-339.
"The Search for Antithrombotic Therapy", Publikationen der Jung-Stiftung Fur Wissenschaft und Forschung, vol. 1, Chapter IV, By H. Hemker, pp. 66-72.
"A Standard for Low Molecular Weight Heparin?", Haemostasis, 1989, By H. Hemker, pp. 1-4.
"The Mode of Action of Heparin in Plasma", Thrombosis and Haemostasis, vol. 60, No. 3, 1988, By S. Beguin et al., pp. 457-462.
"The Mode of Action of Heparin in Plasma", Thrombosis and Haemostasis 1987, By H. Hemker, pp. 17-36.
"The Mode of Action of Low Molecular Weight Heparin Preparation (PK10169) and Two of its Major Components on Thrombin Generation in Plasma", Thrombosis and Haemostasis, vol. 61, No. 1, 1989, By S. Beguin et al., pp. 30-34.
Beguin Suzette L.
Hemker Hendrik C.
LandOfFree
Method for determining the endogenous thrombin potential of plas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for determining the endogenous thrombin potential of plas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for determining the endogenous thrombin potential of plas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-210953